PURPOSE: Methotrexate is a major component of current treatment regimens for children with acute lymphocytic leukemia (ALL). Potential mechanisms of methotrexate resistance include impaired drug uptake, decreased drug retention, and dihydrofolate reductase (DHFR) amplification. The purpose of this study was to assess whether reduced folate carrier (RFC) and DHFR expression in untreated leukemic blasts correlated with outcome. METHODS: Quantitative real-time RT-PCR was used to measure RFC and DHFR mRNA expression in leukemic blasts from 40 newly diagnosed patients with ALL obtained in a blinded fashion from Children's Cancer Group studies. RESULTS: Low RFC expression at diagnosis correlated significantly with an unfavorable event free survival. Surprisingly, low, not high, DHFR expression correlated significantly with an unfavorable event-free survival. Proliferative cell nuclear antigen (PCNA) expression demonstrated a weak inverse relationship between sample PCNA and DHFR or RFC expression, suggesting that DHFR and RFC expression may be markers for factors other than drug resistance. CONCLUSIONS: These results suggest that impaired transport may be an important mechanism of intrinsic methotrexate resistance in ALL, and DHFR expression also may be an important prognostic factor in ALL. Additional studies are necessary to clarify the mechanism for the correlation of low DHFR expression with poor outcome.
PURPOSE:Methotrexate is a major component of current treatment regimens for children with acute lymphocytic leukemia (ALL). Potential mechanisms of methotrexate resistance include impaired drug uptake, decreased drug retention, and dihydrofolate reductase (DHFR) amplification. The purpose of this study was to assess whether reduced folate carrier (RFC) and DHFR expression in untreated leukemic blasts correlated with outcome. METHODS: Quantitative real-time RT-PCR was used to measure RFC and DHFR mRNA expression in leukemic blasts from 40 newly diagnosed patients with ALL obtained in a blinded fashion from Children's Cancer Group studies. RESULTS: Low RFC expression at diagnosis correlated significantly with an unfavorable event free survival. Surprisingly, low, not high, DHFR expression correlated significantly with an unfavorable event-free survival. Proliferative cell nuclear antigen (PCNA) expression demonstrated a weak inverse relationship between sample PCNA and DHFR or RFC expression, suggesting that DHFR and RFC expression may be markers for factors other than drug resistance. CONCLUSIONS: These results suggest that impaired transport may be an important mechanism of intrinsic methotrexate resistance in ALL, and DHFR expression also may be an important prognostic factor in ALL. Additional studies are necessary to clarify the mechanism for the correlation of low DHFR expression with poor outcome.
Authors: Guy J Leclerc; Christopher Sanderson; Stephen Hunger; Meenakshi Devidas; Julio C Barredo Journal: Leuk Res Date: 2010-06-09 Impact factor: 3.156
Authors: Julie Rousseau; Vincent Gagné; Malgorzata Labuda; Cyrielle Beaubois; Daniel Sinnett; Caroline Laverdière; Albert Moghrabi; Stephen E Sallan; Lewis B Silverman; Donna Neuberg; Jeffery L Kutok; Maja Krajinovic Journal: Blood Date: 2011-10-04 Impact factor: 22.113
Authors: Ravi Ramalingam; Harpreet Kaur; Julius Xavier Scott; Latha M Sneha; Ganeshprasad Arunkumar; Arathi Srinivasan; Solomon F D Paul Journal: Cancer Chemother Pharmacol Date: 2022-02-14 Impact factor: 3.333
Authors: Anna Wojtuszkiewicz; Godefridus J Peters; Nicole L van Woerden; Boas Dubbelman; Gabriele Escherich; Kjeld Schmiegelow; Edwin Sonneveld; Rob Pieters; Peter M van de Ven; Gerrit Jansen; Yehuda G Assaraf; Gertjan J L Kaspers; Jacqueline Cloos Journal: J Hematol Oncol Date: 2015-05-29 Impact factor: 17.388
Authors: Michael J Sorich; Nicolas Pottier; Deqing Pei; Wenjian Yang; Leo Kager; Gabriele Stocco; Cheng Cheng; John C Panetta; Ching-Hon Pui; Mary V Relling; Meyling H Cheok; William E Evans Journal: PLoS Med Date: 2008-04-15 Impact factor: 11.069